REZOLUTE
Rezolute is a clinical-stage biopharma specializing in the development of drug therapies for patients with metabolic and orphan diseases. The company is advancing a diversified portfolio including RZ358 (Phase 2), an antibody for the ultra-orphan indication of Congenital HyperInsulinism (CHI), with an abbreviated path-to-market strategy; AB101 (Phase 1), a once-weekly injectable basal insulin with the potential to transform the treatment landscape in diabetes management by reducing the therapeutic burden for patients and improving compliance; and a Plasma Kallikrein Inhibitor (PKI) portfolio with two lead compounds, RZ402 targeting Diabetic Macular Edema (DME) and RZ602 targeting Hereditary Angioedema (HAE), an orphan indication.
REZOLUTE
Industry:
Biotechnology Diabetes Health Care Therapeutics
Founded:
2010-01-01
Address:
Louisville, Colorado, United States
Country:
United States
Website Url:
http://www.rezolutebio.com
Total Employee:
11+
Status:
Active
Contact:
(303) 222-2128
Email Addresses:
[email protected]
Total Funding:
311.6 M USD
Technology used in webpage:
SPF SSL By Default LetsEncrypt Wordpress Plugins Nginx Microsoft Exchange Online Amazon Office 365 Mail GoDaddy DNS Google
Similar Organizations
Aeglea BioTherapeutics
Aeglea BioTherapeutics is a clinical-stage biotechnology company that develops enzyme therapies for rare metabolic diseases.
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Cellular Biomedicine Group
CBMG is a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancers and stem cell therapies.
Chiasma
Chiasma is a biopharmaceutical company developing oral drugs for the treatment of orphan diseases.
Dynacure
Dynacure is a clinical-stage drug development company focused on improving the lives of patients with rare and orphan diseases.
G.I. Windows
G.I. Windows is a clinical-stage company developing the first fundamental breakthrough in surgical anastomotic technology.
Gamida Cell
Gamida Cell is an advanced cell therapy company committed to finding cures for patients with blood cancers and serious blood diseases.
Goldfinch Biopharma
Goldfinch is a clinical-stage biotech company focused on discovering and developing precision therapies for patients with kidney disease.
Gritstone Bio
Gritstone Oncology is a clinical-stage biotech company that develops tumor-specific cancer immunotherapies to fight multiple cancer types.
Kodiak Sciences
Kodiak is designing and developing novel therapies for the treatment of retinal disease.
Kures
Kures is a pre-clinical-stage biopharmaceutical startup that develops opioid-based treatments for depressive disorder.
Milestone Pharmaceuticals
Milestone Pharmaceuticals is a drug development company developing small molecule therapeutics for the treatment of cardiovascular diseases.
Modis Therapeutics
Modis Therapeutics is bringing disease-modifying therapies to patients with rare genetic diseases.
Viking Therapeutics
Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders.
Xeris Pharmaceuticals
Xeris Pharmaceuticals is a pharmaceutical company that develops therapies for patients in endocrinology, neurology, and gastroenterology.
Current Employees Featured
Founder
Stock Details
Investors List
Armentum Partners
Armentum Partners investment in Post-IPO Debt - Rezolute
SLR Capital Partners
SLR Capital Partners investment in Post-IPO Debt - Rezolute
CAM Capital
CAM Capital investment in Post-IPO Equity - Rezolute
BVF Partners
BVF Partners investment in Post-IPO Equity - Rezolute
Federated Kaufmann Fund
Federated Kaufmann Fund investment in Post-IPO Equity - Rezolute
Surveyor Capital
Surveyor Capital investment in Post-IPO Equity - Rezolute
Aju Pharma
Aju Pharma investment in Post-IPO Equity - Rezolute
Medici Investment
Medici Investment investment in Post-IPO Equity - Rezolute
Ildong Pharmaceutical
Ildong Pharmaceutical investment in Post-IPO Equity - Rezolute
pH Pharma
pH Pharma investment in Post-IPO Equity - Rezolute
Key Employee Changes
| Date | New article |
|---|---|
| 2022-06-01 | Rezolute Announces Promotion of Brian Roberts, M.D. to Chief Medical Officer |
Official Site Inspections
http://www.rezolutebio.com
- Host name: 169.214.233.35.bc.googleusercontent.com
- IP address: 35.233.214.169
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Rezolute"
Home - Rezolute, Inc.
Congenital hyperinsulinism (HI) is a rare genetic disease that presents very early in life and is characterized by excess and erratic insulin secretion that can cause infants, children, and …See details»
Rezolute, Inc. | LinkedIn
For more information, visit: www.rezolutebio.com. Rezolute, Inc. | 9,538 followers on LinkedIn. Rezolute is developing transformative therapeutics for rare and metabolic diseases. | Rezolute is a ...See details»
Rezolute - Crunchbase Company Profile & Funding
Rezolute is a clinical-stage biopharma specializing in the development of drug therapies for patients with metabolic and orphan diseases. The company is advancing a diversified portfolio …See details»
Governance :: Rezolute, Inc. (RZLT)
Investor Relations. Oregon Office 2783 NW Lolo Drive Suite 150 Bend, OR 97703See details»
For Patients - Rezolute, Inc.
Whether you have been diagnosed with a condition that leads to frequent hypoglycemia due to elevated insulin levels or you are a representative of a patient advocacy organization for these conditions, we look forward to …See details»
Info :: Rezolute, Inc. (RZLT)
[email protected]. Transfer Agent. Issuer Direct One Glenwood Ave Suite 1001 Raleigh, NC 27603-2582 F: 919-744-2722 [email protected]. Auditor. Grant Thornton …See details»
Rezolute - LifeScienceHistory.com
Www.rezolutebio.com. 275 Shoreline Drive, Suite 500. Redwood City, CA 94065. Company Info Phone (650) 206-4507 Year Established 2010 Ticker RZLT Exchange OTCQB: Contacts …See details»
Contact Us - Rezolute, Inc.
Contact Us - Rezolute, Inc.See details»
Rezolute, Inc. (RZLT)
Investor Relations. Oregon Office 2783 NW Lolo Drive Suite 150 Bend, OR 97703See details»
Rezolute 2025 Company Profile: Stock Performance & Earnings
Rezolute General Information Description. Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary …See details»
Rezolute Receives Breakthrough Therapy Designation from FDA …
Jan 7, 2025 For more information, visit www.rezolutebio.com. Forward-Looking Statements This release, like many written and oral communications presented by Rezolute and our authorized …See details»
Rezolute, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
For more information, visit www.rezolutebio.com. Contact: Rezolute, Inc. Christen Baglaneas [email protected] 508-272-6717 Released January 31, 2025. ... The statistics for …See details»
Join Us - Rezolute, Inc.
Honest: We are driven by a commitment to ethical research and transparent communication, ensuring that our innovations are built on a foundation of trust and integrity. We prioritize …See details»
Rezolute Company Profile - Craft
Oct 29, 2024 Louisville, CO HQ. United States. 1450 Infinite Dr. Bend, OR. United States. 2783 NW Lolo Dr #150. Redwood City, CA. United States. 201 Redwood Shores Pkwy #315See details»
Rezolute Announces Appointment of Rare Disease Commercial …
Mar 26, 2025 For more information, visit www.rezolutebio.com. Forward-Looking Statements This release, like many written and oral communications presented by Rezolute and our …See details»
Rezolute Announces Appointment of Rare Disease Commercial
Mar 27, 2025 For more information, visit www.rezolutebio.com. Forward-Looking Statements This release, like many written and oral communications presented by Rezolute and our …See details»
Rezolute (USA) Funding: $398M - Medical Startups
Apr 24, 2025 Rezolute is a clinical-stage biopharma specializing in the development of drug therapies for patients with metabolic and orphan...See details»
Rezolute Announces Positive Recommendation After Independent …
Apr 23, 2025 For more information, visit www.rezolutebio.com. Forward-Looking Statements This release, like many written and oral communications presented by Rezolute and its …See details»
Rezolute, Inc. Welcomes Pharmaceutical Industry Leader Philippe …
REDWOOD CITY, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (OTCQB:RZLT), announced today that the Company has appointed veteran …See details»
Rezolute, Inc. Announces Closing of Underwritten Offering
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, …See details»